#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Neurodegenerative disorder Fibrosarcoma metastatic Familial haemophagocytic lymphohistiocytosis Acute lymphocytic leukaemia Canavan disease Thalassaemia beta Necrotising enterocolitis neonatal Shprintzen-Goldberg syndrome Dedifferentiated liposarcoma Uveal melanoma Congenital megacolon Blastic plasmacytoid dendritic cell neoplasia Thrombocytopenia Stargardt's disease Arteriosclerosis More trials…

    Learn about Rare Diseases

    X-linked lymphoproliferative syndrome – Basic Information Immunodeficiency congenital – Trials in Disease Biotinidase deficiency – Treatment Idiopathic inflammatory myopathy – Life with Disease Angiosarcoma non-metastatic – Diagnostics Cytokine release syndrome – Treatment Tuberous sclerosis complex – Life with Disease Breast angiosarcoma metastatic – Treatment Ewing’s sarcoma recurrent – Diagnostics Hereditary ataxia – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Topotecan 68Ga-Nota-Abscint-Her2 Ulonivirine Dronabinol Fenebrutinib Mps-214 Pamapimod Human Immunoglobulin G Atezolizumab Adrenaline Tartrate Ph. Eur. Azd8421 Tinengotinib Pyridoxine Hydrochloride Bp Eribulin Gentamicin Sulfate Phenylalanine Chloride Ion Barzolvolimab Quizartinib Dihydrochloride Nemtabrutinib More therapies…

    Learn about Your Condition

    Proteus syndrome Diabetic retinopathy Carotid arteriosclerosis Exudative retinopathy Liposarcoma Hypertrophic cardiomyopathy Affective disorder Hepatitis B Craniotomy Vaginal cancer Influenza Gastrointestinal carcinoma Endometrial cancer recurrent Breast cancer Acromegaly More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Asklepios Kliniken Hamburg GmbH

Asklepios Kliniken Hamburg GmbH

Eissendorfer Pferdeweg 52, Heimfeld, Hamburg, 21075, Germany

Want to learn more about this study or check if you can participate? Contact us.

  • Study of zongertinib tablets in patients with advanced solid tumors that have HER2 gene changes

    Recruiting

    2 1 1
    Investigated Drugs:
    • Zongertinib
    Belgium France Germany Italy The Netherlands Norway +1

  • Study on the Safety and Effectiveness of Teclistamab and Talquetamab for Patients with Newly Diagnosed Multiple Myeloma Eligible for Transplant

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Betamethasone Sodium Phosphate
    • Bortezomib
    • Daratumumab
    Germany

  • Study on the Safety and Effectiveness of Repotrectinib for Patients with ROS1-Positive Non-Small Cell Lung Cancer and Active Brain Metastasis

    Recruiting

    2 1 1
    Investigated Diseases:
    • Metastases to central nervous system
    • Non-small cell lung cancer
    Investigated Drugs:
    • Repotrectinib
    Austria Germany Spain

  • Study of Iberdomide and Isatuximab for Maintenance Therapy in Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Iberdomide
    • Dexamethasone
    • Isatuximab
    Austria Germany

  • Study on the Effectiveness and Safety of Tinengotinib for Patients with Cholangiocarcinoma Resistant to Chemotherapy and FGFR Inhibitors

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Cholangiocarcinoma
    Investigated Drugs:
    • Tinengotinib
    • Irinotecan Hydrochloride Trihydrate
    • Fluorouracil
    Austria Belgium France Germany Italy Poland +2

  • Study of Zenocutuzumab for Patients with Solid Tumors with NRG1 Fusion

    Recruiting

    2 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Zenocutuzumab
    Austria Belgium Denmark France Germany Italy +4

  • Study of PC14586 for Patients with Advanced Solid Tumors with a Specific TP53 Mutation

    Recruiting

    2 1 1
    Investigated Diseases:
    • Lung neoplasm malignant
    • Breast cancer
    • Endometrial cancer
    Investigated Drugs:
    • Pc14586
    France Germany Italy Spain

  • Study Comparing Elranatamab to Drug Combinations for Patients with Relapsed/Refractory Multiple Myeloma After Anti-CD38 Therapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma refractory
    Investigated Drugs:
    • Elranatamab
    • Bortezomib
    • Carfilzomib
    Belgium Croatia Czechia Denmark Finland France +10

  • Study on Pelacarsen for Slowing Calcific Aortic Valve Stenosis in Patients

    Recruiting

    2 1
    Investigated Drugs:
    • Pelacarsen
    Austria Belgium Czechia Denmark France Germany +4

  • Study of Tucatinib, Trastuzumab, and mFOLFOX6 for Patients with HER2+ Metastatic Colorectal Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Tucatinib
    • Bevacizumab
    • Cetuximab
    Austria Belgium France Germany Greece Hungary +8
Previous Page
1 … 3 4 5 6 7 … 13
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!